Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers
On January 5, 2023, Laboratory Corporation of America® Holdings ("Labcorp")
announced that Thomas (Tom) Pike will join Labcorp as president and chief
executive officer of its Drug Development Clinical Development business unit
effective January 9, 2023 (the "Effective Date"), and, upon completion of the
previously announced planned spin-off of Labcorp's Clinical Development
business, Mr. Pike will become chief executive officer and chairman of the Board
of Directors of the spun-off company. Mr. Pike will report to Labcorp's
President, CEO and Chairman of the Board of Directors as of the Effective Date
until completion of the spin-off.
On January 4, 2023, Paul Kirchgraber, EVP and CEO of Labcorp's Drug Development
business segment informed Labcorp that he intends to depart Labcorp upon the
completion of the planned spin-off in order to pursue other opportunities. Until
completion of the planned spin-off, Labcorp expects that Dr. Kirchgraber will
continue to lead the Company's Early Development, Central Laboratories and
Global Oncology businesses within the Drug Development business segment and
that, in connection with the appointment of Mr. Pike, effective as of the
Effective Date, Dr. Kirchgraber will no longer lead the Drug Development
Clinical Development business unit.
Item 7.01 Regulation FD Disclosure
On January 5, 2023, Labcorp issued a press release announcing Mr. Pike's
appointment. The full text of the press release is attached hereto as Exhibit
99.1.
Item 9.01 Financial Statements and Exhibits.
Exhibit Exhibit Name
Exhibit 99.1 Press release dated January 5 , 202 3 issued by Labcorp
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
LABCORP HOLDINGS INC. 
